Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Publication Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…Certara2013 年 9 月 1 日
Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data Publication Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data Results from clinical trials are never interpreted in isolation. Previous studies in a similar setting…Certara2013 年 9 月 1 日
Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study Publication Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5,…Certara2013 年 9 月 1 日
Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) Publication Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) The impact of transporters in modulating the disposition of drugs in the liver and their…Certara2013 年 8 月 20 日
Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy Publication Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. The objective…Certara2013 年 8 月 15 日
Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development Publication Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic (PBPK)…Certara2013 年 8 月 1 日
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis Publication Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis Clinical trial simulation (CTS) and model-based meta-analysis (MBMA) can increase our understanding of small, first-in-patient…Certara2013 年 7 月 24 日
A Mechanistic Framework for In Vitro-In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug-drug Interaction Between Rosuvastatin and Cyclosporine Publication A Mechanistic Framework for In Vitro-In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug-drug Interaction Between Rosuvastatin and Cyclosporine The interplay between liver metabolizing enzymes and transporters is a complex process involving system-related parameters such as liver blood perfusion…Certara2013 年 7 月 24 日
Model-based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development Publication Model-based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development The pharmaceutical industry continues to face significant challenges. Very few compounds that enter development reach…Certara2013 年 7 月 1 日
The Simcyp Population-based Simulator: Architecture, Implementation, and Quality Assurance Publication The Simcyp Population-based Simulator: Architecture, Implementation, and Quality Assurance Developing a user-friendly platform that can handle a vast number of complex physiologically based pharmacokinetic…Certara2013 年 6 月 3 日